Evommune (EVMN) Company presentation summary

Program positioning

• EVO570 is an oral VAV1 molecular glue degrader positioned as a potential first-in-class therapy, with JAK-like efficacy potential and an improved safety profile.

• VAV1 is presented as an immune-cell-specific regulator of T- and B-cell receptor signaling, with potential across autoimmune indications.

• RA is the lead proof-of-concept indication; the development strategy identifies 12 prioritized VAV1 indications for potential expansion.

Biological rationale and market opportunity

• VAV1 loss of function is associated with impaired T- and B-cell proliferation and function, cytokine production, immunoglobulin production, and T-cell-dependent B-cell responses.

• VAV1 biology overlaps with seven approved drug classes across nine indications; direct evidence cited includes genetics, disease models, patient cells, and ongoing or posted Phase 2a/b trials.

• More than 50% of RA patients are not in remission; anti-TNF efficacy can wane, and TNF-refractory patients have limited options.

• RA is intended as a 12-week, placebo-controlled study in MTX-inadequate responders, pairing clinical endpoints with target engagement.

Preclinical profile

• EVO570 showed 0.3 nM VAV1 DC50 and 99% maximum degradation; reported functional potency was 0.08 nM in T-cell IL-2 and 0.06 nM in B-cell IL-6 assays.

• Versus MRT-6160, EVO570 was reported ~20x more potent for VAV1 degradation, with ~4x stronger ternary-complex activity and ~10–12x greater T- and B-cell functional potency.

• Selectivity and safety findings included no degradation of VAV3, GSPT1, IKZF or SALL4, hERG IC50 >15 μM, negative Ames test, and a >1,000x therapeutic window.

• Oral bioavailability exceeded 80% across four species; efficacy was reported in CIA, EAE and IBD models at 0.01–0.1 mpk.